findmyKOL
Clinical trialNCT06411821RecruitingPhase 2Interventional

Ulixertinib in People With Histiocytic Neoplasms

SponsorMemorial Sloan Kettering Cancer CenterEnrollment38Histiocytic Neoplasms
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The researchers are doing this study is to find out whether ulixertinib is an effective and safe treatment for people with histiocytic neoplasms.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Mayo Clinic (data Collection Only)

    Rochester, Minnesota, United States

    Recruiting
  • Memorial Sloan Kettering Basking Ridge (consent Only)

    Basking Ridge, New Jersey, United States

    Recruiting
  • Memorial Sloan Kettering Monmouth (limited Protocol Activities)

    Middletown, New Jersey, United States

    Recruiting
  • Memorial Sloan Kettering Bergen (consent Only)

    Montvale, New Jersey, United States

    Recruiting
  • Memorial Sloan Kettering Suffolk-Commack (consent Only)

    Commack, New York, United States

    Recruiting
  • Memorial Sloan Kettering Westchester (limited Protocol Activities)

    Harrison, New York, United States

    Recruiting
  • Memorial Sloan Kettering Cancer Center (all Protocol Activities)

    New York, New York, United States

    Eli Diamond, MD
    Recruiting
  • Memorial Sloan Kettering Nassau (consent Only)

    Uniondale, New York, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ulixertinib
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
7 May 2024
Primary completion
31 May 2027
Completion
31 May 2027
Last update posted
28 May 2026
Registered enrollment
38
Registry id
NCT06411821

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.